Sandoz Group AG
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland, with most of global functions operating from Holzkirchen in Germany, Prague in Czechia, and Barcelona in Spain. Sandoz is the global leader in generic pharmaceuticals and biosimilars.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of SDZ-SW would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2023) — listing | $6,865 1.7× | $10,113 1.7× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Headquarters
Basel, Switzerland
Popular scenarios with SDZ
For illustration only — not investment advice. Past performance is not indicative of future results.